A 3-judge panel questioned the legitimacy of Johnson & Johnson’s plan to form a subsidiary company with the purpose of absorbing legal liabilities from talc-related lawsuits.
Posts
The Swiss competition commission (COMCO) has opened an investigation of Novartis over possible unlawful use of a patent to reduce competitive pressure, the Swiss drugmaker confirmed on Thursday.
A federal judge on Tuesday dismissed, for the second time, a whistleblower lawsuit accusing drugmaker Novartis AG of paying kickbacks to doctors through a sham speaker program to promote its multiple sclerosis drug Gilenya.
inch Therapeutics is slashing its headcount by around 37% and suspending its planned Phase I study in autism one week after Takeda withdrew from its multi-year collaboration, the company announced Thursday.
Novartis said on Monday its Scemblix was approved by the European Commission for adult patients with chronic myeloid leukemia (CML), offering a new treatment approach for patients with intolerance to other therapies.
Novartis CEO Vas Narasimhan could struggle to woo investors to the listing of generics drugs business Sandoz, as weaker drug prices and jittery financial markets present one of his biggest challenges in the years-long overhaul of the Swiss drugmaker.
Novartis plans to spin off its underperforming generics unit Sandoz to sharpen its focus on its patented prescription medicines, the Swiss group said on Thursday, acknowledging it had not received any formal offers for the business to date.
With financial backing from Medicxi, Vaderis Therapeutics AG emerged from stealth mode Monday with a focus on allosteric AKT inhibitors and a clinic-ready drug candidate.
The U.S. Food and Drug Administration on Wednesday approved bluebird bio’s gene therapy for patients with a rare disorder requiring regular blood transfusions, and the drugmaker priced it at a record $2.8 million.
On Monday, Novartis released results from the Phase III CANOPY-A trial, showing that its candidate canakinumab (ACZ885) failed to meet its primary efficacy endpoint in adult non-small cell lung cancer (NSCLC) patients.
